Skip to main content
Paul Sondel, MD, Pediatric Hematology & Oncology, Madison, WI, UnityPoint Health Meriter

PaulMSondelMD

Pediatric Hematology & Oncology • Madison, WI

Professor of Pediatrics, University Wisc

Join to view full profile

Dr. Sondel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Sondel's full profile

Already have an account?

Education & Training

  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsResidency, Pediatrics, 1978 - 1980
  • University of Minnesota
    University of MinnesotaInternship, Pediatrics, 1977 - 1978
  • Harvard Medical School
    Harvard Medical SchoolClass of 1977

Certifications & Licensure

  • WI State Medical License
    WI State Medical License 1978 - 2025
  • American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2002-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Elected Member The American Society for Clinical Investigation, 1988
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • To Save Children with Cancer, Doctors Turn to New Weapons
    To Save Children with Cancer, Doctors Turn to New WeaponsAugust 5th, 2022
  • First-in-Humans Clinical Trial to Treat Children with Relapsed Neuroblastoma Opens at American Family Children’s Hospital
    First-in-Humans Clinical Trial to Treat Children with Relapsed Neuroblastoma Opens at American Family Children’s HospitalNovember 19th, 2020
  • New Clinical Trial for Advanced Melanoma Patients Seeks to Turn Tumors Against Themselves
    New Clinical Trial for Advanced Melanoma Patients Seeks to Turn Tumors Against ThemselvesOctober 23rd, 2019
  • Join now to see all

Grant Support

  • The Role Of KIR And Fcr Genotype In The Efficacy Of MAB And IL2 ImmunotherapyNational Cancer Institute2012
  • Antitumor Mechanisms Of Anti-Cd40/Cpg-Activated MacrophagesNational Cancer Institute2008–2011
  • Clinical Development Of Hu14.18-Il2 Targeted TherapyNational Cancer Institute2006–2011
  • Phase I Study Of Fenretinide LXS Oral Powder In Patients With NeuroblastomaNational Center For Research Resources2007
  • Phase II Trial Of Hu1418-Il2 (Emd 273063) In Subjects With Advanced MelanomaNational Center For Research Resources2006–2007
  • 131I-MIBG With Intensive Chemotherapy And Autologous Stem Cell RescueNational Center For Research Resources2006–2007
  • T-Cell Independent Antitumor Mechanisms Of CD40 LigationNational Cancer Institute2002–2005
  • Phase I Trial Of Hu14.18-Il-2 In Neuroblastoma And Other Gd2+ TumorsNational Center For Research Resources2004
  • Clinical Development Of Hu14.18 IL2 Targeted TherapyNational Cancer Institute2000–2004
  • Phase I Study Of Taxol In Refractory Leukemia In ChildrenNational Center For Research Resources1999–2002
  • Maintenance Treatment Of Therapy Refractory All W/ B43 PAP ImmunotoxiNational Center For Research Resources1999–2002
  • Systemic Immunity By Particle Mediated BRM Gene TransferNational Cancer Institute1996–1999
  • Clinical Testing Of Ch1418-Il2 For Gd2+ TumorsNational Cancer Institute1996–1998
  • Antibody IL-2 Fusion Protein Delivery By Gene TransferNational Cancer Institute1996–1998
  • Phase I Trial Of Melanoma Reactive Ch.14.18 PLUS IL2 In Adults With MelanomaNational Center For Research Resources1995–1996
  • In Vitro Reactivity And Regulation Of Lymphocyte Response In LymphocytesNational Center For Research Resources1995
  • Combined Modality Antibody Directed Cell CytotoxicityNational Cancer Institute1995
  • Combined Modality Antibody-Directed Cell CytotoxicityNational Cancer Institute1993–1995
  • Antitumor Artificial Receptors As Cancer VaccinesNational Cancer Institute1992–1995
  • Immunobiology Of Antileukemic LymphocytesNational Cancer Institute1994
  • Clinical Studies Of Biological Response ModifiersDivision Of Cancer Treatment1990–1994
  • Immunobiology Of Human Antileukemic LymphocytesNational Cancer Institute1990–1993
  • BRM Monitoring Of Pediatric Neuroblastoma/OsteosarcomaNational Cancer Institute1990–1991
  • Autologous LAK Cells &Il-2 In Cancer PatientsDivision Of Cancer Treatment1987–1990
  • The Immunobiology Of Human Antileukemic LymphocytesNational Cancer Institute1985–1989
  • Clinical Trial Of Natural And Recombinent Interleukin-2Division Of Cancer Treatment1986
  • Core--Scintillation Counting ServicesNational Cancer Institute1985

Professional Memberships

Hospital Affiliations

Dr. Paul Sondel, Dr. Paul Sondel, MD, Dr. P Sondel, Dr. Paul M Sondel